News

Here's what to know about the FDA's COVID-19 vaccine changes
The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.
Officials have been questioning safety, efficacy of mRNA vaccines. What we know
Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were ...
With vaccine approval process set to change, FDA advisers leave wiggle room in annual Covid-19 shot recommendations
A group of experts who advise the US Food and Drug Administration on its vaccine decisions voted unanimously Thursday to make ...
What the New COVID-19 Vaccine Guidance Means For You
Here’s how COVID-19 vaccine guidance is changing in the U.S. For people at high risk of severe COVID-19. The process of ...
You asked: Are vaccines approved without safety studies?
No, this is not true. Vaccines undergo rigorous safety testing and are continuously monitored for adverse events.
Trump FDA overhauls COVID-19 vaccine approval to focus on older populations, high-risk individuals
The FDA announced a policy shift for COVID-19 vaccine approvals to focus on Americans considered high-risk of contracting the ...
Trump Administration Plans Not To Recommend COVID-19 Vaccines For Pregnant People, Teenagers, and Children: WSJ
Secretary Robert F. Kennedy Jr., who leads the Department of Health and Human Services, will soon announce the changes to the ...
FDA Updates COVID-19 Vaccine Regulations—Here’s What to Know
The FDA has updated COVID-19 vaccine regulations. Only people aged 65 and up, along with certain groups, will be eligible to ...
FDA requires Covid vaccine makers to expand warning about risk of rare heart inflammation
The US Food and Drug Administration will now require Covid-19 vaccines from Pfizer/BioNTech and Moderna to use expanded ...
Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 ...